These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32659428)

  • 41. Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo.
    Li Y; Quan J; Song H; Li D; Ma E; Wang Y; Ma C
    Bioorg Chem; 2021 Sep; 114():105081. PubMed ID: 34153811
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
    Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects.
    Miao JF; Peng YF; Chen S; Gao WJ; Yang QX; Zhu P; Guo J; Tao J; Luo L; Zhang Y; Ling Y
    Eur J Pharmacol; 2018 Apr; 824():78-88. PubMed ID: 29428472
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells.
    Reddy ND; Shoja MH; Biswas S; Nayak PG; Kumar N; Rao CM
    Chem Biol Interact; 2016 Jun; 253():112-24. PubMed ID: 27163855
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
    Porter NJ; Mahendran A; Breslow R; Christianson DW
    Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
    Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
    Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
    Wang F; Zhong BW; Zhao ZR
    J Biol Regul Homeost Agents; 2018; 32(4):851-858. PubMed ID: 30043566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
    Tavares MT; Kozikowski AP; Shen S
    Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis.
    Gao YS; Hubbert CC; Lu J; Lee YS; Lee JY; Yao TP
    Mol Cell Biol; 2007 Dec; 27(24):8637-47. PubMed ID: 17938201
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin-induced apoptosis in castration-resistant prostate cancer.
    Ye PC; Leu WJ; Yeh TY; Hsu YT; Lin YC; Wei ZY; Chen YC; Chiang YC; Hsu JL; Chan SH; Hsu LC; Chern JW; Yu CW; Guh JH
    Prostate; 2024 May; 84(6):605-619. PubMed ID: 38375594
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel class of anthraquinone-based HDAC6 inhibitors.
    Song Y; Lim J; Seo YH
    Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
    Reßing N; Sönnichsen M; Osko JD; Schöler A; Schliehe-Diecks J; Skerhut A; Borkhardt A; Hauer J; Kassack MU; Christianson DW; Bhatia S; Hansen FK
    J Med Chem; 2020 Sep; 63(18):10339-10351. PubMed ID: 32803970
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2/p53 pathway.
    Wang XN; Wang KY; Zhang XS; Yang C; Li XY
    Biochem Biophys Res Commun; 2018 Oct; 504(4):812-819. PubMed ID: 30217455
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
    Fiskus W; Rao R; Fernandez P; Herger B; Yang Y; Chen J; Kolhe R; Mandawat A; Wang Y; Joshi R; Eaton K; Lee P; Atadja P; Peiper S; Bhalla K
    Blood; 2008 Oct; 112(7):2896-905. PubMed ID: 18660379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of HDAC6 activity through interaction with RanBPM and its associated CTLH complex.
    Salemi LM; Maitland MER; Yefet ER; Schild-Poulter C
    BMC Cancer; 2017 Jul; 17(1):460. PubMed ID: 28668087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer.
    Dong J; Zheng N; Wang X; Tang C; Yan P; Zhou HB; Huang J
    Eur J Pharmacol; 2018 Jun; 828():67-79. PubMed ID: 29563065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension.
    Boucherat O; Chabot S; Paulin R; Trinh I; Bourgeois A; Potus F; Lampron MC; Lambert C; Breuils-Bonnet S; Nadeau V; Paradis R; Goncharova EA; Provencher S; Bonnet S
    Sci Rep; 2017 Jul; 7(1):4546. PubMed ID: 28674407
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6.
    Qu X; Du J; Zhang C; Fu W; Xi H; Zou J; Hou J
    PLoS One; 2012; 7(2):e32215. PubMed ID: 22384180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sensitization of tumor cells by targeting histone deacetylases.
    Perego P; Zuco V; Gatti L; Zunino F
    Biochem Pharmacol; 2012 Apr; 83(8):987-94. PubMed ID: 22120677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.